April 2, 2018 / 8:21 PM / 8 months ago

BRIEF-Daré Bioscience Says Intends To Communicate With U.S. FDA In Mid-2018 Regarding Phase 2b Study Of Topical Sildenafil

1 Min Read

April 2 (Reuters) - Dare Bioscience Inc:

* DARÉ BIOSCIENCE, INC. REPORTS 2017 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

* DARE BIOSCIENCE - INTENDS TO COMMUNICATE WITH U.S. FDA IN MID-2018 REGARDING PHASE 2B STUDY OF TOPICAL SILDENAFIL

* ANTICIPATES COMMENCING A PHASE 2B STUDY OF TOPICAL SILDENAFIL IN Q4 OF 2018 Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below

All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.

© 2018 Reuters. All Rights Reserved.